Results 91 to 100 of about 7,770 (204)
What role for real-world evidence in market access of biosimilars?
Experience with the use of biosimilars in real-life practice provides an excellent opportunity to collect real-world evidence aimed at addressing residual uncertainties about biosimilars.
Steven Simoens +2 more
doaj +1 more source
Inflammatory Bowel Disease: Mechanisms and Therapeutic Advances
Inflammatory bowel disease (IBD), encompassing ulcerative colitis and Crohn's disease, is a rising, multifactorial chronic disorder driven by dysregulated mucosal immunity in genetically susceptible individuals and influenced by environmental and microbial factors.
Andrea Papait +5 more
wiley +1 more source
The use of adalimumab biosimilars has become increasingly common in clinical practice, reflecting their growing acceptance and efficacy as therapeutic alternatives to reference biologics.
Andrea Di Santo +8 more
doaj +1 more source
ABSTRACT Aim To evaluate and compare the efficacy, safety, and immunogenicity of a synthetic semaglutide injection (Test semaglutide) with Wegovy (Reference semaglutide) injection for weight management. Materials and Methods This randomized, Phase III, non‐inferiority study included adults with obesity or overweight with or without comorbidities from ...
Unnikrishnan Ambika Gopalakrishnan +26 more
wiley +1 more source
Background. The increasing number of registered biosimilars of monoclonal antibodies (mAbs) is altering the structure of the pharmaceutical market by amplifying the share of domestic manufacturers.
A. Yu. Efremov +5 more
doaj +1 more source
ABSTRACT Frontline blinatumomab combined with chemotherapy has resulted in improved outcomes in both pediatric and adult patients with acute lymphoblastic leukemia and is considered the new cornerstone of acute lymphoblastic leukemia treatment. The role of asparaginase in this new landscape of acute lymphoblastic leukemia treatment was extensively ...
Daniel J. DeAngelo +15 more
wiley +1 more source
ObjectiveTo evaluate the impact of the entry of biosimilars on the pricing of eight biologic products in 57 countries and regions.MethodsWe utilized an interrupted time series design and IQVIA MIDAS® data to analyze the annual sales data of eight ...
Hui-Han Chen +2 more
doaj +1 more source
Objective To evaluate the six‐month effectiveness and safety of rituximab biosimilars compared to the originator in granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), and outcomes following originator to biosimilar switching. Methods We recruited adults with GPA or MPA treated with the rituximab originator or a biosimilar for ...
Arielle Mendel +14 more
wiley +1 more source
Objective To evaluate the efficacy and safety of guselkumab, an interleukin‐23p19 subunit inhibitor, in participants with active psoriatic arthritis (PsA) and inadequate response (inadequate efficacy and/or intolerance) to one prior tumor necrosis factor (TNF) inhibitor.
Alexis Ogdie +12 more
wiley +1 more source
Aims The aim of this study was to introduce a new assessment method for pharmacy students' real‐life competence in reviewing medications after obligatory advanced‐level practical internship in Finland. Methods The new medication review (MR) competence assessment method consisted of (1) a self‐assessment by pharmacy students and (2) a performance ...
Katja Leiman +5 more
wiley +1 more source

